While converting many EU data sources to OMOP model, we ran into a common issue of drug cost as the health care system is different there compared to US. Would it be possible to think of a way to support EU drug cost in the upcoming models?
I know @jenniferduryea has already made some good arguments for changing the cost table in CDM for the US and I think many members in the community are going to welcome a change in CDMv6. I think the international view point will be helpful and has even been asked for.
Please see this post:
@Christian_Reich I wasn’t able to attend the CDM discussion at the F2F, did this come up?
It would also be great to have an example of European cost data. From what I have seen, it is typically cost data (not charges, and not reimbursed amounts). If so, it should fit in any of the cost tables. If there are specific reimbursement-related components to the cost, then we have to see what they look like to know whether they will, or will not, work with the proposed changes. So, examples (variables and definitions) would be helpful.